[go: up one dir, main page]

CR20210521A - Glicoproteínas saliladas - Google Patents

Glicoproteínas saliladas

Info

Publication number
CR20210521A
CR20210521A CR20210521A CR20210521A CR20210521A CR 20210521 A CR20210521 A CR 20210521A CR 20210521 A CR20210521 A CR 20210521A CR 20210521 A CR20210521 A CR 20210521A CR 20210521 A CR20210521 A CR 20210521A
Authority
CR
Costa Rica
Prior art keywords
shear stress
salilated
glycoproteins
stable
pharmaceutical
Prior art date
Application number
CR20210521A
Other languages
English (en)
Inventor
Siddhesh D Patil
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=72837963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20210521(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CR20210521A publication Critical patent/CR20210521A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se describen preparaciones farmacéuticas que contienen inmunoglobulinas hipersialiladas. Las preparaciones son estables al esfuerzo de cizalla. Las composiciones farmacéuticas descritas en la presente descripción proporcionan composiciones de hsIgG farmacéuticamente aceptables que son estables contra el esfuerzo de cizalla (p. ej., no se forman un número significativo de partículas subvisibles cuando la formulación se somete a esfuerzo de cizalla, tal como agitación, por ejemplo, durante el envío) y, por lo tanto, pueden enviarse y manipularse en forma líquida
CR20210521A 2019-04-18 2020-04-17 Glicoproteínas saliladas CR20210521A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (1)

Publication Number Publication Date
CR20210521A true CR20210521A (es) 2022-04-01

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210521A CR20210521A (es) 2019-04-18 2020-04-17 Glicoproteínas saliladas

Country Status (21)

Country Link
US (1) US20220211849A1 (es)
EP (1) EP3955962A4 (es)
JP (1) JP2022529168A (es)
KR (1) KR20220002963A (es)
CN (1) CN113795275B (es)
AU (1) AU2020259492A1 (es)
BR (1) BR112021020509A8 (es)
CA (1) CA3137101A1 (es)
CL (1) CL2021002668A1 (es)
CO (1) CO2021013926A2 (es)
CR (1) CR20210521A (es)
EA (1) EA202192860A1 (es)
EC (1) ECSP21078309A (es)
IL (1) IL287306A (es)
JO (1) JOP20210281A1 (es)
MX (1) MX2021012710A (es)
PE (1) PE20220383A1 (es)
PH (1) PH12021552468A1 (es)
SG (1) SG11202110942SA (es)
WO (1) WO2020215021A1 (es)
ZA (1) ZA202109184B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
EP4248218A1 (en) 2020-11-20 2023-09-27 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111608A2 (en) * 2003-06-09 2004-12-23 Mcintyre John A Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
JP2009503105A (ja) * 2005-08-03 2009-01-29 イミュノジェン・インコーポレーテッド 免疫複合体製剤
CA2763138A1 (en) * 2009-05-27 2010-12-02 Baxter International Inc. A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
WO2014052360A2 (en) * 2012-09-26 2014-04-03 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
EP3719122A1 (en) * 2013-05-02 2020-10-07 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
WO2014191240A1 (en) * 2013-05-29 2014-12-04 F. Hoffmann-La Roche Ag Quantitative control of sialylation
EP3058084A4 (en) * 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
AU2018207367B2 (en) * 2017-01-11 2024-02-15 Celltrion Inc. Stable Liquid Formula

Also Published As

Publication number Publication date
EA202192860A1 (ru) 2021-12-23
BR112021020509A2 (pt) 2022-03-15
CL2021002668A1 (es) 2022-05-27
JP2022529168A (ja) 2022-06-17
CO2021013926A2 (es) 2021-10-29
CA3137101A1 (en) 2020-10-22
KR20220002963A (ko) 2022-01-07
ECSP21078309A (es) 2021-11-30
EP3955962A1 (en) 2022-02-23
CN113795275A (zh) 2021-12-14
JOP20210281A1 (ar) 2023-01-30
US20220211849A1 (en) 2022-07-07
IL287306A (en) 2021-12-01
MX2021012710A (es) 2021-11-12
CN113795275B (zh) 2025-03-07
AU2020259492A1 (en) 2021-11-11
ZA202109184B (en) 2023-04-26
PE20220383A1 (es) 2022-03-18
WO2020215021A1 (en) 2020-10-22
EP3955962A4 (en) 2022-12-14
SG11202110942SA (en) 2021-11-29
PH12021552468A1 (en) 2022-06-13
BR112021020509A8 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
ECSP21078309A (es) Glicoproteínas sialiladas
CO2019011021A2 (es) Formulacion estable de anticuerpos
CL2018003604A1 (es) Composiciones farmacéuticas para terapia combinada (divisional solicitud 201701983)
MX2022003572A (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
MX2017012877A (es) Composiciones gomosas de multicomponentes con nucleo suave.
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
CO2018012502A2 (es) Formulaciones y métodos para el tratamiento de organismos fotosintéticos y la mejora de las calidades y cantidades de rendimientos con formulaciones de compuestos de glicano
CO2020005366A2 (es) Composición plaguicida que contiene tidiazurón y ácido poliglutámico
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
BR112022001330A2 (pt) Derivados de 3,6-diamino-piridazin-3-ila, composições farmacêuticas contendo-os e seus usos como agentes pró-apoptóticos
MX377345B (es) Composición que tiene residuo reducido.
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2016016148A (es) Preparacion de rocuronio con estabilidad mejorada.
AR118881A1 (es) Composiciones de virus inactivado y formulaciones de vacuna contra el zika
PH12022551148A1 (en) Injectable compositions of ursodeoxycholic acid
BR102020012866A8 (pt) Composições tópicas contendo derivados de n-acil-dipeptídeo e ácido glicólico
BR112019023074A2 (pt) composição contendo ciclodextrina e bussulfano
BR112019000240A2 (pt) composições farmacêuticas
BR112018074143A2 (pt) composição tópica estável e método de tratamento de infecções fúngicas
PH12022550938A1 (en) Products and methods using sonication to increase bioactivity of soy peptides
CO2021004612A2 (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento
CO2021016879A2 (es) Formulaciones estabilizadas de ditiocarbamatos
AR123578A1 (es) Mezclas de polisorbato que tienen distribución de ésteres de ácidos grasos modificados
PH12019501049A1 (en) Pharmaceutical composition containing palonosetron as active ingredient